Exploring growth characteristics of AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH).

In this article we will dive into AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) as a possible candidate for growth investing. Investors should always do their own research, but we noticed AMPHASTAR PHARMACEUTICALS IN showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

Why NASDAQ:AMPH may be interesting for growth investors.

• AMPHASTAR PHARMACEUTICALS IN has achieved an impressive Return on Equity (ROE) of 22.73%, showcasing its ability to generate favorable returns for shareholders.
• With a track record of beating EPS estimates in the last 4 quarters, AMPHASTAR PHARMACEUTICALS IN showcases its consistent ability to deliver earnings surprises. This reflects the company's strong execution and its competitive position in the market.
• With impressive 1-year revenue growth of 24.02%, AMPHASTAR PHARMACEUTICALS IN showcases its ability to generate increased sales and revenue. This growth highlights the company's strong customer demand and its effective business strategies.
• The q2q revenue growth of 50.3% of AMPHASTAR PHARMACEUTICALS IN highlights the company's ability to generate incremental revenue and suggests positive market demand for its products or services.
• AMPHASTAR PHARMACEUTICALS IN has shown positive growth in its operating margin over the past year, indicating improved operational efficiency. This growth highlights the company's ability to effectively manage costs and maximize profitability.
• With a favorable trend in its free cash flow (FCF) over the past year, AMPHASTAR PHARMACEUTICALS IN demonstrates its ability to generate robust cash flows and maintain financial stability. This growth reflects the company's focus on efficient capital allocation and cash management.
• The earnings per share (EPS) of AMPHASTAR PHARMACEUTICALS IN have shown positive growth on a quarter-to-quarter (Q2Q) basis, with a 203.0% increase. This reflects the company's ability to improve its profitability over time.
• Over the past 3 months, analysts have adjusted their EPS Estimate for AMPHASTAR PHARMACEUTICALS IN with a 25.73% change. This highlights the evolving outlook on the company's EPS potential.
• The recent financial report of AMPHASTAR PHARMACEUTICALS IN demonstrates a 203.0% increase in quarterly earnings compared to the previous quarter. This growth indicates positive momentum in the company's financials and suggests a promising upward trend
• accelerating EPS growth for AMPHASTAR PHARMACEUTICALS IN: the current Q2Q growth of 203.0% exceeds the previous year Q2Q growth of -17.39%.

What is the full fundamental picture of NASDAQ:AMPH telling us.

At ChartMill, a crucial aspect of their analysis is the assignment of a Fundamental Rating to each stock. This rating, ranging from 0 to 10, is calculated daily by considering numerous fundamental indicators and properties.

We assign a fundamental rating of 7 out of 10 to AMPH. AMPH was compared to 206 industry peers in the Pharmaceuticals industry. While AMPH has a great profitability rating, there are some minor concerns on its financial health. AMPH has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! These ratings could make AMPH a good candidate for value and growth investing.

For an up to date full fundamental analysis you can check the fundamental report of AMPH

Our Lois Navellier screen will find you more ideas suited for growth investing.

Keep in mind

This is not investing advice! The article highlights some of the observations at the time of writing, but you should always make your own analysis and invest based on your own insights.